Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- ICH-S9 Guideline to Apply to Non-Clinical Studies for “Serious Malignancies”
January 19, 2016
- New ICH Trial Guidelines to Embrace “Pooled Populations,” but PMDA Unlikely to Accept Zero Japanese
January 18, 2016
- MHLW Taskforce on Vaccines, Blood Products Kicks Off Discussions
January 15, 2016
- Research-Driven Makers Should Find Another Biz Model If They Can’t Innovate: Top Bureaucrat
January 15, 2016
- Fulminant Hepatitis to Be Added to List of Significant Adverse Reactions to Amlodipine Products
January 14, 2016
- AMED, US NIH Ink Memorandum of Cooperation for Orphan Diseases, Cancer
January 13, 2016
- Kaketsuken Ordered Record 110-Day Suspension, Shiozaki Says He Won’t Allow It to Remain As-Is
January 12, 2016
- Re-Pricing Rule for “Huge-Seller” Drugs Necessary Compromise to Protect Universal Healthcare While Promoting Innovation: Health Minister
January 12, 2016
- Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
- Careful Administration Re-stressed for Inavir, Relenza in Dairy-Sensitive Patients: Safety Bulletin
January 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for December 2015
January 8, 2016
- Shipment of Some Lots of Kaketsuken’s Kenketsu Globulin OK’ed
January 7, 2016
- Health Policy Bureau’s FY2016 Draft Budget Earmarks 5.7 Billion Yen to Promote Clinical Research
January 5, 2016
- Health Service Bureau Increases Budgets for Measures against Hepatitis, Infectious Diseases: FY2016 Draft Budget
January 5, 2016
- Gist of FY2016 Drug Pricing Reform
December 25, 2015
- Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
- 130 Million Yen Earmarked to Boost PMDA Staffers for Accelerating Review: FY2016 Budget
December 25, 2015
- MHLW Looked at Innovativeness, Seriousness of Target Disease to Select Sakigake Products
December 25, 2015
- MHLW Launches Confab to Shore Up Healthcare Startup Sector
December 25, 2015
- Drug Price Cuts to Save 174.9 Billion Yen in State Coffers: MOF
December 25, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…